We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+13.5%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$71.7M
AUM Growth
+$18M
(+33%)
Cap. Flow
+$11.5M
Cap. Flow
% of AUM
16.1%
Top 10 Holdings %
Top 10 Hldgs %
66.95%
Holding
32
New
12
Increased
6
Reduced
9
Closed
5
Top Buys
| 1 |
GSK
GSK
|
+$3.63M |
| 2 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
+$3.11M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$2.7M |
| 4 |
Inogen
INGN
|
+$2.24M |
| 5 |
PTC Therapeutics
PTCT
|
+$1.64M |
Top Sells
| 1 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$2.2M |
| 2 |
DaVita
DVA
|
+$1.25M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$1.16M |
| 4 |
Edwards Lifesciences
EW
|
+$956K |
| 5 |
Incyte
INCY
|
+$943K |
Sector Composition
| 1 | Healthcare | 90.17% |
| 2 | Industrials | 6.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$6.52B
| $6.1M | 8.51% |
620,334
+135,755
| +28% | +$1.64M |
|
2
Centene
CNC
$32.8B
| $5.61M | 7.82% |
157,360
-21,778
| -12% | -$729K |
|
|
SGYP
3
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $5.09M | 7.09% |
1,091,768
+536,683
| +97% | +$3.11M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$15.5B
| $4.89M | 6.82% |
33,691
-8,906
| -21% | -$1.16M |
|
|
HMSY
5
DELISTED
HMS Holdings Corp.
HMSY
| $4.83M | 6.74% |
237,802
-26,958
| -10% | -$497K |
|
6
Bio-Rad Laboratories Class A
BIO
$8.15B
| $4.53M | 6.31% |
22,713
+4,395
| +24% | +$847K |
|
|
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
| $4.53M | 6.31% |
634,865
-121,731
| -16% | -$770K |
|
8
Eli Lilly
LLY
$1.05T
| $4.51M | 6.28% |
53,583
-3,401
| -6% | -$272K |
|
9
UnitedHealth
UNH
$387B
| $4.17M | 5.81% |
25,392
+9,733
| +62% | +$1.59M |
|
|
10
GSK
GSK
$104B
| $3.77M | 5.26% |
+71,612
| New | +$3.63M |
|
11
Quest Diagnostics
DGX
$23.3B
| $3.67M | 5.12% |
37,385
+7,900
| +27% | +$753K |
|
|
12
Sarepta Therapeutics
SRPT
$1.82B
| $2.58M | 3.6% |
+87,180
| New | +$2.7M |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $2.56M | 3.57% |
27,318
-1,407
| -5% | -$127K |
|
|
14
Inogen
INGN
$178M
| $2.51M | 3.5% |
+32,393
| New | +$2.24M |
|
|
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
| $2.21M | 3.09% |
48,800
-15,295
| -24% | -$682K |
|
|
16
Incyte
INCY
$23.4B
| $1.73M | 2.41% |
12,931
-7,406
| -36% | -$943K |
|
17
Puma Biotechnology
PBYI
$434M
| $1.58M | 2.21% |
+42,524
| New | +$1.55M |
|
18
Ironwood Pharmaceuticals
IRWD
$635M
| $1.4M | 1.95% |
97,731
+29,240
| +43% | +$400K |
|
19
Biogen
BIIB
$30.4B
| $840K | 1.17% |
+3,073
| New | +$869K |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
| $826K | 1.15% |
+39,696
| New | +$879K |
|
21
Syndax Pharmaceuticals
SNDX
$2.02B
| $824K | 1.15% |
+60,087
| New | +$624K |
|
22
Cardinal Health
CAH
$53.5B
| $819K | 1.14% |
+10,049
| New | +$791K |
|
23
AstraZeneca
AZN
$262B
| $773K | 1.08% |
+12,405
| New | +$722K |
|
24
Acadia Healthcare
ACHC
$3.17B
| $519K | 0.72% |
+11,915
| New | +$483K |
|
|
KERX
25
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $421K | 0.59% |
+68,381
| New | +$375K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Asymmetry Capital Management held 32 positions worth $71.7M, up 33% from $53.8M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Asymmetry Capital Management deployed $11.5M of net new capital in Q1 2017, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was GSK: 71,612 shares worth $3.77M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.16M trimmed.
- Asymmetry Capital Management's largest Q1 2017 buy was GSK: 71,612 shares worth $3.77M.
- Asymmetry Capital Management added most to Synergy Pharmaceuticals, Inc Common Stock in Q1 2017, an estimated $3.11M increase.
- Asymmetry Capital Management's biggest Q1 2017 reduction was Jazz Pharmaceuticals, cutting an estimated $1.16M.
- Asymmetry Capital Management fully exited Impax Laboratories, Inc. in Q1 2017, selling an estimated $2.2M.
- Asymmetry Capital Management's ten largest holdings make up 67% of its $71.7M portfolio in Q1 2017.
- Asymmetry Capital Management opened 12 new positions and closed 5 in Q1 2017.
- Asymmetry Capital Management's portfolio value rose 33% quarter-over-quarter to $71.7M.
Based on Asymmetry Capital Management's 13F filing for Q1 2017, filed 12 May 2017.